News

Leadership Change at City Electric Supply Signals New Era

Leadership Change at City Electric Supply Signals New Era

Leadership Transition at City Electric Supply

City Electric Supply (CES) is entering an exciting new phase as Co-Chief Executive Officer Andrew Dawes prepares for retirement after an exemplary 33-year journey. Taking the reins will be Blair Feidler, who currently serves as the Vice President of Operations.

Passing the Torch

After a remarkable career dedicated to CES, Dawes will officially step down on April 30, 2026. His invaluable contributions over the years have shaped the direction and strength of the company. In a seamless transition, Feidler is set to take on the role of co-CEO, working alongside Co-CEO John Gray.

Words from Leadership

"Andrew has been an exceptional leader whose contributions have helped strengthen the company and our people over the years," said Global CEO Jeremy Saunders. "His commitment to excellence at every level has been vital for CES. We wish him the best in his retirement and thank him for his service."

Reflections on Leadership

John Gray shared his thoughts, saying, "I've had the privilege of working with Andrew throughout the years. His insight and dedication have left a lasting impact on the company and everyone involved. It has genuinely been an honor to work alongside such a friend and partner."

A Legacy of Growth

Dawes's tenure at CES is marked by significant growth and leadership, initiating his journey in 1992 as a driver. Through hard work and ambition, he climbed the ranks to become vice president of operations for CES Canada and later co-chief operating officer in the U.S. His visionary leadership played a crucial role in expanding CES’s fulfillment network from one location to six across North America, showcasing his commitment to innovation.

Looking Forward

"With its culture of ownership and opportunity, my time at CES has been a remarkable journey," Dawes reflected. "I'm grateful for the relationships and experiences that defined my career here. I leave with pride in our accomplishments together."

Blair Feidler Steps Up

Blair Feidler's promotion is indicative of the company’s practice of nurturing leadership from within. Having been a part of the CES team since 1997, Feidler has distinguished himself in various roles, moving from driver and warehouse associate to regional manager and vice president of operations. His journey mirrors the company's strong belief in promoting talent from within.

Plans for Continued Success

Anthony Gray stated, "I met Blair early in his career and witnessed his drive. He embodies the core values of CES and, like Andrew and me, has made his way up from the branches. I'm excited about partnering with him and continuing our impactful culture."

Commitment to Transition

As Andrew Dawes transitions into retirement and Blair Feidler integrates into his new role as co-CEO, CES is dedicated to finalizing succession plans. The smooth transition aims to uphold the company's momentum and success while ensuring that operational integrity remains intact.

Frequently Asked Questions

What is the role of Andrew Dawes at City Electric Supply?

Andrew Dawes is the Co-Chief Executive Officer who will retire soon, concluding a 33-year career with the company.

Who will succeed Andrew Dawes as co-CEO?

Blair Feidler, the Vice President of Operations, will succeed Dawes as co-CEO.

When is Andrew Dawes's retirement date?

Dawes is scheduled to retire on April 30, 2026.

What has been Andrew Dawes's contribution to CES?

Dawes has played a significant role in the growth and operational success of CES since he started with the company in 1992.

How does CES promote leadership within the company?

CES focuses on developing leaders from within, emphasizing opportunities for growth and advancement across all levels of the organization.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading